Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

Basit Öğe Kaydı
dc.contributor.authorYildiz, Ibrahim
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorOzer, Leyla
dc.contributor.authorTural, Deniz
dc.contributor.authorKaplan, Mehmet A.
dc.contributor.authorAkman, Tulay
dc.date.accessioned2024-04-24T17:27:34Z
dc.date.available2024-04-24T17:27:34Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.en_US
dc.identifier.doi10.5301/tj.5000635
dc.identifier.endpage450en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue6en_US
dc.identifier.pmid28731496
dc.identifier.scopus2-s2.0-85063322484
dc.identifier.scopusqualityQ3
dc.identifier.startpage444en_US
dc.identifier.urihttps://doi.org/10.5301/tj.5000635
dc.identifier.urihttps://hdl.handle.net/11468/20061
dc.identifier.volume104en_US
dc.identifier.wosWOS:000454667200024
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrain Metastasisen_US
dc.subjectPrognostic Factoren_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectSurvivalen_US
dc.subjectTargeted Therapyen_US
dc.titlePrognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapyen_US
dc.titlePrognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu